Zhejiang Jiuzhou Pharmaceutical Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Zhejiang Jiuzhou Pharmaceutical has been growing earnings at an average annual rate of 26.9%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 20.5% per year. Zhejiang Jiuzhou Pharmaceutical's return on equity is 8.1%, and it has net margins of 14.2%.
Anahtar bilgiler
26.9%
Kazanç büyüme oranı
24.8%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 10.9% |
| Gelir büyüme oranı | 20.5% |
| Özkaynak getirisi | 8.1% |
| Net Marj | 14.2% |
| Son Kazanç Güncellemesi | 30 Sep 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Shares Leap 25% Yet They're Still Not Telling The Full Story
Oct 01
Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Seems To Use Debt Quite Sensibly
Sep 25Here's Why Zhejiang Jiuzhou Pharmaceutical (SHSE:603456) Can Manage Its Debt Responsibly
Jun 13Zhejiang Jiuzhou Pharmaceutical Co., Ltd's (SHSE:603456) Business And Shares Still Trailing The Market
May 24Zhejiang Jiuzhou Pharmaceutical's (SHSE:603456) Solid Earnings May Rest On Weak Foundations
May 01Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next
Apr 11Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate
Feb 28Gelir ve Gider Dağılımı
Zhejiang Jiuzhou Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Sep 24 | 4,912 | 697 | 475 | 331 |
| 30 Jun 24 | 5,033 | 886 | 480 | 324 |
| 31 Mar 24 | 5,248 | 989 | 538 | 317 |
| 31 Dec 23 | 5,523 | 1,033 | 544 | 331 |
| 30 Sep 23 | 5,649 | 1,145 | 507 | 300 |
| 30 Jun 23 | 5,745 | 1,075 | 493 | 288 |
| 31 Mar 23 | 5,823 | 994 | 499 | 302 |
| 31 Dec 22 | 5,445 | 921 | 474 | 287 |
| 30 Sep 22 | 5,432 | 904 | 524 | 279 |
| 30 Jun 22 | 5,150 | 827 | 516 | 258 |
| 31 Mar 22 | 4,581 | 747 | 429 | 202 |
| 31 Dec 21 | 4,063 | 634 | 391 | 173 |
| 30 Sep 21 | 3,906 | 614 | 388 | 160 |
| 30 Jun 21 | 3,507 | 526 | 332 | 152 |
| 31 Mar 21 | 3,112 | 443 | 371 | 132 |
| 31 Dec 20 | 2,647 | 381 | 347 | 114 |
| 30 Sep 20 | 2,404 | 341 | 346 | 105 |
| 30 Jun 20 | 2,167 | 265 | 371 | 98 |
| 31 Mar 20 | 2,010 | 227 | 317 | 96 |
| 31 Dec 19 | 2,017 | 238 | 283 | 95 |
| 30 Sep 19 | 1,952 | 198 | 283 | 91 |
| 30 Jun 19 | 1,800 | 171 | 273 | 88 |
| 31 Mar 19 | 1,785 | 149 | 266 | 89 |
| 31 Dec 18 | 1,862 | 157 | 283 | 87 |
| 30 Sep 18 | 1,752 | 128 | 242 | 81 |
| 30 Jun 18 | 1,839 | 163 | 199 | 126 |
| 31 Mar 18 | 1,798 | 157 | 216 | 99 |
| 31 Dec 17 | 1,717 | 148 | 221 | 85 |
| 30 Sep 17 | 1,696 | 139 | 252 | 65 |
| 30 Jun 17 | 1,694 | 147 | 305 | 0 |
| 31 Mar 17 | 1,697 | 116 | 297 | 0 |
| 31 Dec 16 | 1,653 | 111 | 284 | 0 |
| 30 Sep 16 | 1,559 | 118 | 248 | 0 |
| 30 Jun 16 | 1,500 | 126 | 244 | 0 |
| 31 Mar 16 | 1,458 | 197 | 253 | 0 |
| 31 Dec 15 | 1,445 | 200 | 260 | 0 |
| 30 Sep 15 | 1,432 | 195 | 270 | 0 |
| 30 Jun 15 | 1,349 | 170 | 243 | 0 |
| 31 Mar 15 | 1,325 | 142 | 209 | 0 |
| 31 Dec 14 | 1,286 | 133 | 193 | 0 |
| 30 Sep 14 | 1,229 | 155 | 167 | 0 |
| 31 Dec 13 | 1,310 | 166 | 180 | 0 |
Kaliteli Kazançlar: 603456 has high quality earnings.
Büyüyen Kar Marjı: 603456's current net profit margins (14.2%) are lower than last year (20.3%).
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 603456's earnings have grown significantly by 26.9% per year over the past 5 years.
Büyüme Hızlandırma: 603456's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Kazançlar vs. Sektör: 603456 had negative earnings growth (-39.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.2%).
Özkaynak Getirisi
Yüksek ROE: 603456's Return on Equity (8.1%) is considered low.